John G Ullman & Associates Inc. Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

John G Ullman & Associates Inc. bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,631,000.

Several other institutional investors and hedge funds also recently made changes to their positions in JAZZ. Rise Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter. Cape Investment Advisory Inc. increased its holdings in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares during the last quarter. Assetmark Inc. increased its holdings in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares during the last quarter. Headinvest LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter worth about $56,000. Finally, Newbridge Financial Services Group Inc. increased its holdings in Jazz Pharmaceuticals by 254.5% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 336 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $3.81 during trading hours on Thursday, reaching $106.04. The stock had a trading volume of 484,704 shares, compared to its average volume of 687,495. The stock’s fifty day simple moving average is $107.82 and its 200 day simple moving average is $115.60. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The firm has a market capitalization of $6.69 billion, a PE ratio of 21.86, a PEG ratio of 1.55 and a beta of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The firm had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. On average, equities research analysts predict that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Piper Sandler raised their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. StockNews.com downgraded shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, July 5th. Stifel Nicolaus increased their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price for the company. Finally, Barclays cut their target price on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $188.62.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.